Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Targeting LRRC15-expressing fibroblasts holds therapeutic potential to ameliorate inflammation and fibrosis in autoimmune diseases.

Rheumatology (Oxford, England)·2026

Same author

Stochastic Morphodynamics of the Human Aorta Across the Lifespan.

medRxiv : the preprint server for health sciences·2026

Same author

A 98-qubit trapped-ion quantum computer with all-to-all connectivity.

Nature·2026

Same author

Personalized modeling of stress and blood pressure reactivity using mobile health data.

Npj mental health research·2026

Same author

Discovery of Novel <i>N</i>-Linked Camptothecin Linker-Payloads to Access Antibody-Drug Conjugates with High Target-Mediated In Vivo Efficacy.

Journal of medicinal chemistry·2026

Same author

Design of Novel Exatecan-Amide Linker-Payloads for the Development of Stable, Low-Aggregating, and Highly Efficacious Antibody-Drug Conjugates.

Journal of medicinal chemistry·2026

Same journal

Discovery and optimization of a pH-responsive ultra-long-acting VHH-based growth hormone mimetic.

mAbs·2026

Same journal

Efficient inference of non-polyreactive antibody variants dependent on local fine-tuning.

mAbs·2026

Same journal

Impact of ASO conjugation and receptor binding affinity on intracellular transport of mono- and bispecific TfR- and CD98-Brainshuttle<sup>TM</sup> variants.

mAbs·2026

Same journal

Development of single-chain C1q affinity chromatography-mass spectrometry for the glycoform-resolved characterization of low-affinity immunoglobulin G interactions.

mAbs·2026

Same journal

Biparatopic targeting of IL-23 enables dual-epitope engagement and enhanced neutralization potency.

mAbs·2026

Same journal

Comparison of knockdown approaches for the generation of stable cell populations expressing afucosylated antibodies.

mAbs·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Dec 25, 2025

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations

Published on: August 22, 2019

Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.

Marc Bailly¹, Carl Mieczkowski¹, Veronica Juan¹

¹Discovery Biologics, Protein Sciences, South San Francisco, CA, USA.

|April 7, 2020

Summary

This summary is machine-generated.

A high-throughput developability workflow assesses physicochemical properties of monoclonal antibodies early in drug development. This process efficiently selects optimal antibody candidates, streamlining the CMC phase and enabling timely engineering.

Keywords:

CMC Monoclonal antibodies antibody discovery antibody screening biophysical properties developability manufacturability protein analytics protein engineering

More Related Videos

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

Related Experiment Videos

Last Updated: Dec 25, 2025

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations

Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations

Published on: August 22, 2019

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

Area of Science:

Biopharmaceutical development
Protein engineering
Drug discovery

Background:

Monoclonal antibodies are crucial therapeutics across various medical areas.
Developability, assessing physicochemical properties, is key for successful drug progression.
Early evaluation of antibody developability is vital for efficient candidate selection.

Purpose of the Study:

To establish a high-throughput workflow for assessing monoclonal antibody developability.
To correlate biophysical properties with downstream process parameters.
To enable early elimination of suboptimal antibody candidates.

Main Methods:

Analysis of 152 monoclonal antibodies using biophysical property assays.
Implementation of a high-throughput workflow for early-stage screening.
Evaluation of binding affinity, biological properties, and physicochemical parameters.

Main Results:

Established correlations between different biophysical assays.
Demonstrated that physicochemical properties correlate with downstream process parameters in case studies.
Successfully eliminated antibodies with suboptimal properties through the workflow.

Conclusions:

The developed workflow efficiently ranks antibody candidates based on developability.
Early identification and engineering of problematic antibody attributes are facilitated.
Streamlined candidate selection accelerates the CMC phase and overall drug development timelines.